Brown Rudnick represents Lupin in connection with its acquisition of Symbiomix Therapeutics
PUBLISHED ON: 10/27/2017
RELATED EXPERIENCESHOW MORE
Brown Rudnick represented transnational pharmaceutical company Lupin in connection with its acquisition of Symbiomix Therapeutics, LLC, a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. Symbiomix recently received FDA approval of Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women. The acquisition has been made for a cash consideration of USD 150 million including a USD 50 million upfront and other time-based payments. In addition, there are sales based contingent payments. The Brown Rudnick team was led by partners Rob Funsten and Katy Gardner and included associates Jen Charles and Mary Ambacher. Support for the transaction was provided by partners Adam Cantor and Vince Guglielmotti and associates Stephanie Bollheimer and Nicole Bouchard (tax/employee benefits) and partner Mark Leonardo (intellectual property). Additional support was provided by partner Jason McCaffrey and associate Cailin Harris.